Subacute thyroiditis in the SARS-CoV-2 era: a multicentre prospective study
Authors' conclusion
This is the first prospective study investigating any difference both at diagnosis and at follow-up between SAT presentation in patients with previous SARS-CoV-2 infection and those without. Our data demonstrate that SARS-CoV-2 does not impact on SAT onset, evolution, and outcome.
Study context
- Population
- Patients diagnosed with subacute thyroiditis (SAT), November 2020 to May 202241 completed follow-up
- Participants
- 66 patients
- Exposure
- SAT with prior SARS-CoV-2 infection vs without
- COVID+n = 7
- Outcome
- Prior SARS-CoV-2 infection (IgG) before SAT diagnosis
- Follow-up
- Baseline
Methodological detailsmulticentre, longitudinal, 3-year
- Multicentre
- Longitudinal
- 3-year
Main finding
As reported in the abstract
- Infection before SAT diagnosis (COVID+)
- 7 out of 52 subjects (13.5%)
- Respiratory symptoms more common in COVID+
- P = 0.039
- Fever more common in COVID+
- P = 0.021
Observational data: associations, not effects.
Further findings
Pain at baseline
- Presented with pain
- 54
- Pain for at least 15 days
- 36 (67%)
Therapeutic approach and outcome during follow-up · 1, 3, 6 and 12 months
- COVID+ and COVID- did not differ for therapeutic approach to SAT or outcome; all improved in neck pain, inflammation parameters and US features
- 41 subjects completed follow-up
Original publication
Subacute thyroiditis in the SARS-CoV-2 era: a multicentre prospective study. Eur Thyroid J. Published 24 June 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →